RPI ID: 2019-025-401

Innovation Summary:
This invention introduces a method for assessing treatment response in individuals with autism spectrum disorder (ASD) using multivariate statistical analysis. It applies Fisher discriminant analysis to metabolic profile data from folate-dependent one-carbon metabolism and transsulfuration pathways. The system distinguishes between typically developing individuals and those with ASD before and after treatment. This approach enables objective, data-driven evaluation of therapeutic efficacy.

Challenges / Opportunities:
Evaluating treatment outcomes in ASD is often subjective and lacks standardized biomarkers. This invention addresses the need for quantitative, reproducible methods to assess biological response to interventions. It opens opportunities for personalized medicine and more effective clinical trials in neurodevelopmental disorders.

Key Benefits / Advantages:
✔ Objective assessment using metabolic biomarkers
✔ Data-driven approach employing multivariate statistical modeling
✔ Supports individualized treatment strategies in personalized medicine
✔ Enhances research and therapeutic development in ASD

Applications:
• Autism treatment monitoring
• Clinical trial evaluation
• Biomarker discovery
• Neurodevelopmental research

Keywords:
#Autismspectrumdisorder #treatmentresponse #multivariateanalysis #metabolicprofiling #Fisherdiscriminant

Intellectual Property:
US Issued Patent 11,699,530 B2